Citations

Clear

167 citation(s) found for "Grogan, M".

Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis
Tan, Nicholas Y. , MOHSIN, YOUSEF, Hodge, David O. , Lacy, Martha Q. , Packer, Douglas L. , Dispenzieri, Angela , Grogan, Martha , Asirvatham, Samuel J. , Madhavan, Malini , McLeod, Christopher J. , Dispenzieri, Angela , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 16, 2016 | Volume: 27 | Issue: 10 | Pages: 1167-1173

10.1111/jce.13046 | PMID 27422772 Get It

Catheter Ablation for Atrial Arrhythmias in Patients With CABackgroundCardiac amyloidosis (CA) is associated with increased atrial arrhythmias risk. The efficacy/safety of catheter‐based ablation therapy in patients with CA has not been adequately assessed.Methods and ResultsAll diagnosed CA patients who underwent atrial arrhythmia ablation therapy from 1995 to 2015 were reviewed. Arrhythmia recurrence, NYHA symptoms, and mortality were recorded. A total of 26 patients with CA and atrial arrhythmias were included; there were 7 light‐chain (AL), 17 wild‐type transthyretin (ATTRwt), and 2 mutated transthyretin (ATTRm) amyloidosis patients in total. Of which 13 underwent atrial arrhythmia ablation (CA‐A) and 13 underwent AV nodal ablation (CA‐AVN). In the CA‐A group, there were: 3 with atrial fibrillation (AF); 6 with atrial flutter (AFL); 2 with AF/AFL; and 2 with atrial tachycardia (AT). One‐year and 3‐year recurrence‐free survival were 75% and 60%, respectively. NYHA symptom improvement 6 months postablation was observed in both CA‐A and CA‐AVN groups: 7/10 (70%) and 4/8 (50%), respectively. Eleven patients with CA died (8 in CA‐AVN group vs. 3 in CA‐A group).ConclusionsCatheter‐based ablation for patients with CA appears to provide important symptomatic relief. However, mortality from the underlying disease remains a significant issue for the amyloid light‐chain subtype.
Abnormal stress echocardiography findings in cardiac amyloidosis
Ong, Kevin , Askew, J. Wells , Dispenzieri, Angela , Maleszewski, Joseph J. , Klarich, Kyle W. , Anavekar, Nandan S., Grogan, Martha , Mulvagh, Sharon L. , Dispenzieri, Angela

Mayo Clinic

Amyloid | May 2, 2016 | Volume: 23 | Issue: 2 | Pages: 124-131

10.1080/13506129.2016.1176020 | PMID 27132767 Get It

Right Parasternal Lead Placement Increases Eligibility for Subcutaneous Implantable Cardioverter Defibrillator Therapy in Adults With Congenital Heart Disease
Okamura, Hideo , Webster, Tracy L., Bonnichsen, Crystal R. , Grogan, Martha , Phillips, Sabrina D. , Connolly, Heidi M. , Ammash, Naser M., Warnes, Carole A. , Friedman, Paul A. , McLeod, Christopher J. , DeSimone, Christopher V.

Mayo Clinic

Circulation Journal | April 21, 2016 | Volume: 80 | Issue: 6 | Pages: 1328-1335

10.1253/circj.cj-16-0153 | PMID 27109124 Get It

Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases
Larsen, Brandon T. , Dasari, Surendra , Fayyaz, Ahmed, Theis, Jason D. , Vrana, Julie A., Grogan, Martha , Dispenzieri, Angela , Edwards, William D. , Kurtin, Paul J. , Maleszewski, Joseph J. , Mereuta, Oana M, Fayyaz, Ahmed U., Doǧan, Ahmet , Mereuta, Oana Madalina , Dispenzieri, Angela

Mayo Clinic

Histopathology | July 25, 2015 | Volume: 68 | Issue: 5 | Pages: 648-656

10.1111/his.12793 | PMID 26212778 Get It

Aims Prognostication and treatment selection for cardiac amyloidosis requires accurate amyloid typing. The aim of this study was to investigate the utility of histomorphology for predicting type. Methods and results Autopsy cases with cardiac amyloidosis (1998–2010) were typed by the use of mass spectrometry‐based proteomics. Deposition patterns were correlated with amyloid type. Among 108 decedents (mean age 75 years; 69% men), 107 had a single type, including transthyretin (ATTR) (60 cases), amyloid light chain (AL) (32 λ; 12 κ), amyloid A (AA) (two), and apolipoprotein AIV (AApoAIV) (one). Interstitial deposition was more extensive in AL amyloidosis cases than in ATTR cases [odds ratio (OR) 6.8, P = 0.0004]. Histomorphological patterns of interstitial deposition were mixed in 61% of AL amyloidosis cases and in 61% of ATTR cases, but diffuse pericellular deposits favoured AL amyloidosis (OR 10.7, P = 0.0001), nodular deposits favoured ATTR (OR 3.1, P = 0.0229), and discrete pericellular deposits tended to partially favour ATTR (OR 1.7, P = 0.1970). Arterial and venous deposits each favoured AL amyloidosis (OR ranging from 9.3 to 192.0, P‐value ranging from 0.0022 to <0.0001), and were severe in AL amyloidosis. Endocardial deposits favoured AL amyloidosis (OR 46.3, P < 0.0001) and were also more severe in AL amyloidosis. Conclusions The extent and distribution of cardiac amyloidosis strongly correlate with amyloid type, suggesting fundamental differences in the pathobiology of deposition. The tendency for mixed patterns to occur limits the practicality and accuracy of using histopathology for amyloid typing.
Soluble suppression of tumorigenicity 2 (sST2), but not galactin‐3, adds to prognostication in patients with systemic AL amyloidosis independent of NT‐proBNP and troponin T
Dispenzieri, Angela , Saenger, Amy K., Kumar, Shaji , Lacy, Martha Q. , Dingli, David , Leung, Nelson , Zeldenrust, Steven R., Hayman, Suzanne R. , Kapoor, Prashant , Grogan, Martha , Hwa, Yi L. , Russell, Stephen J. , Kyle, Robert A. , Jaffe, Allan S. , Saenger, Amy, Buadi, Francis K. , Zeldenrust, Steven, Hwa, Lisa, Jaffe, Allan, Gertz, Morie A. , Go, Ronald S. , Rajkumar, S. Vincent , Jaffe, Allan S. , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David

Mayo Clinic

American Journal of Hematology | March 9, 2015 | Volume: 90 | Issue: 6 | Pages: 524-528

10.1002/ajh.24001 | PMID 25753178 Get It

The use of soluble cardiac biomarkers such as N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) and troponin has revolutionized prognostication for patients with AL amyloidosis. Soluble ST2 (sST2) and galectin‐3 have also been reported to have prognostic value in other cardiac patient populations. We identified 502 patients with AL amyloidosis, who provided a research sample and consent to review their medical records between 1/1/2006‐12/31/2010 within 90 days of their diagnosis. Samples were assayed for sST2 and galectin‐3. Within this AL amyloidosis population, overall survival (OS) was 25.5 months (95% CI 18, 35.7 months). Receiver operating curve analyses were done to detect the best cut‐points for sST2 and galectin‐3 to predict both 1‐ and 5‐year OS. The respective cut points for sST2 were 30 and 29.7 ng/mL, while the median sST2 for the entire population was 31 ng/mL (IQR 19.8, 53.6). The respective cut points for galectin‐3 were 11 and 10.4 ng/mL while the median for the entire population was 16.6 ng/mL (IQR 11.5, 24.0). Although on univariate analysis, both sST2 and galectin‐3 were prognostic, upon multivariate analysis, only sST2 was independent of troponin, NT‐proBNP, serum immunoglobulin free light chain, and blood pressure. Not only did sST2 add to previously reported prognostication systems, but a novel prognostication 5‐point system including sST2 was possible. The addition of sST2 – but not galectin‐3 – to existing prognostication systems for patients with AL amyloidosis strengthens the ability to predict for death. Am. J. Hematol. 90:524–528, 2015. © 2015 Wiley Periodicals, Inc.
Minimally Invasive Video-Assisted Surgical Closure of Atrial Septal Defects
Sabaté-Rotés, Anna , Burkhart, Harold M. , Suri, Rakesh M. , Grogan, Martha , Taggart, Nathaniel W. , Schaff, Hartzell V. , Li, Zhuo , Suri, Rakesh M. , Li, Zhuo Ya , Dearani, Joseph A. , Taggart, Nathaniel W , Schaff, Hartzell

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | October 16, 2014 | Volume: 5 | Issue: 4 | Pages: 527-533

10.1177/2150135114542166 | PMID 25324249 Get It

Objective: To compare the safety and effectiveness of video-assisted thoracic surgery (VATS) versus conventional median sternotomy (open) in the repair of secundum atrial septal defect (ASD) or patent foramen ovale (PFO). Design: Among 415 consecutive patients undergoing open or VATS ASD/PFO closure between 1993 and October 2012, 153 patients were compared using 2:1 frequency matching (n = 102 open vs 51 VATS). Matching variables include age, gender, body surface area, past medical history of neurologic events, and need of patch closure. Median age was 43 years (3-71 years), and 67% were female. Results: There were no early deaths in either group. There were no conversions to open sternotomy. Although mean cross-clamp time (14.5 ± 7.6 vs 26.3 ± 13.2 minutes, P < .001) and bypass time (31.7 ± 13.8 vs 60.9 ± 20.9 minutes, P < .001) were longer in the VATS group, patients who underwent VATS had shorter postoperative ventilation time (7.5 ± 6.4 vs 4.4 ± 2.8 hours, P = .03) with 62.7% extubated in the operating room, along with shorter intensive care unit stay (26.7 ± 10.8 vs 19.1 ± 9.9 hours, P < .001) and hospital stay (5.2 ± 1.9 vs 3.5 ± 0.9 days, P < .001). At early follow-up (mean 1.5 years, maximum 4.2 years), there was no difference in need for reintervention. Of the 27 patients who underwent VATS ASD/PFO closure for a neurologic event, none had a recurrence. Conclusion: The use of VATS provides a safe, equally effective alternative to conventional sternotomy for ASD/PFO closure, using a less invasive approach.
Pulmonary masses in a patient with dyspnea: Apply Occam's razor or Hickam's dictum?
Leung, Nelson , Grogan, Martha , Johnson, Geoffrey B. , Klecka, Mary E., Dispenzeiri, Angela, Johnson, Geoffrey B. , Leung, Nelson , Johnson, Geoffrey B , Johnson, Geoffrey B

Mayo Clinic

American Journal of Hematology | October 9, 2014 | Volume: 90 | Issue: 5 | Pages: 462-465

10.1002/ajh.23870 | PMID 25297538 Get It

Abstract LB-296: FDG-PET avidity negatively impacts survival in pStage I NSCLC in the ACOSOG Z4031 trial.
Grogan, Eric L. , Deppen, Stephen A. , Chen, Heidi , Ballman, Karla V. , Verdial, Francys C. , Aldrich, Melinda C. , Decker, Paul A. , Harpole, David H., Cerfolio, Robert J. , D’Amico, Thomas A., Shrager, Joseph B. , Meyers, Bryan F., Decker, Paul A. , Keenan, Robert J. , Jones, David R. , Meyers, Bryan F. , Putnam, Joe B. , Ballman, Karla

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: LB-296-LB-296

10.1158/1538-7445.am2013-lb-296 Get It

Abstract Background: Fluoro-deoxyglucose positron emission tomography (FDG-PET) scans are used for diagnosis and staging of known or suspected non-small cell lung cancer (NSCLC). Single institution studies examining the impact of avidity on survival have reported mixed results. The purpose of this study is to evaluate the association between FDG-PET avidity and survival in the national prospective ACOSOG Z4031 trial in patients with pathological Stage I NSCLC. Methods: Between 2004 and 2006, 1074 patients with known or suspected clinical stage I (cT1-2N0M0) NSCLC were enrolled in the ACOSOG Z4031 trial and underwent surgical resection. FDG-PET results were abstracted from radiology interpretations included in the case report forms. FDG-PET avidity was categorized based on either radiologist description or reported maximum standard uptake value (SUV). The four categories were: 1) not avid and not cancerous (SUV=0), 2) low avidity and likely not cancerous (SUV&gt;0 and &lt;2.5), 3) avid and probably cancerous (SUV≥2.5 and &lt;5) and 4) highly avid and likely cancerous (SUV≥5). The lesion was classified as avid if in categories 3 or 4. The final diagnosis was determined by pathological examination and all cause mortality was reported. Cox proportional hazard regression was used to assess the impact of FDG-PET avidity on survival. The covariates used in the model included pStage, gender, age, race, and preoperative lesion size. Kaplan-Meier survival curves were calculated and the log-rank test was used to determine differences in survival based on FDG-PET avidity. Results: There were 51 enrolling sites in 39 cities with 969 eligible participants. Preoperative FDG-PET results were available for 540 participants with NSCLC and 81% had FDG-PET avid or highly avid lesions. 400 patients had pStage I NSCLC and the 5 year survival was 70% with 95%CI (65%, 75%). FDG-PET avidity, male gender, age, and lesion size negatively impacted survival. FDG-PET avidity in pStage I disease still negatively impacted survival (p=0.03) when controlling for lesion size. The 5 year survival for Stage I disease was 80% with 95%CI (68%, 88%) in FDG-PET negative patients and 67% with 95% CI (61%, 72%) in FDG-PET positive patients (p=0.02). Conclusions: In a national surgical population with pathological stage I NSCLC, FDG-PET avidity negatively impacted five year survival, independently of lesion size. Further work should be done to determine if chemotherapy would be beneficial in patients with PET avid lesions and pStage I NSCLC. Citation Format: Eric L. Grogan, Stephen A. Deppen, Heidi Chen, Karla V. Ballman, Francys C. Verdial, Melinda C. Aldrich, Paul A. Decker, David H. Harpole, Robert J. Cerfolio, Robert J. Keenan, David R. Jones, Thomas A. D'Amico, Joseph B. Shrager, Bryan F. Meyers, Joe B. Putnam. FDG-PET avidity negatively impacts survival in pStage I NSCLC in the ACOSOG Z4031 trial. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-296. doi:10.1158/1538-7445.AM2013-LB-296
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis
Dispenzieri, Angela , Kumar, Shaji , Lacy, Martha Q. , Kyle, Robert A. , Saenger, Amy K., Grogan, Martha , Zeldenrust, Steven R., Hayman, S. R., Greipp, Philip R., Russell, Stephen J. , Dingli, David , Lust, John A., Rajkumar, S. Vincent , Jaffe, Allan S. , Gertz, Morie A. , Buadi, Francis K. , Leung, Nelson , Jaffe, Allan S. , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David

Mayo Clinic

Heart | January 9, 2014 | Volume: 100 | Issue: 5 | Pages: 383-388

10.1136/heartjnl-2013-304957 | PMID 24402772 Get It

Objectives To define whether the high sensitivity cardiac troponin T (hs-cTnT) assay in patients with immunoglobulin light chain amyloidosis (AL) improves risk prediction. Background Cardiac involvement is the major cause of death in patients with AL amyloidosis. Risk stratification is facilitated by cardiac biomarkers such as cardiac troponin T (cTnT) and N-terminal pro B-type natriuretic peptide (NT-proBNP). Methods Stored serum from patients with newly diagnosed AL was used to measure hs-cTnT, cTnT, and NT-proBNP. Survival modelling was performed. Results The direct numeric result from hs-cTnT measurement cannot merely be substituted for a cTnT measurement in the Mayo AL staging system. The performance of the receiver operator curve derived an hs-cTnT cut-point of 54 ng/L which improves on the value of 35 ng/L validated with the prior iteration of the assay. An alternate staging option using hs-cTnT alone—using the two thresholds 14 ng/L and 54 ng/L—performs as well as either the original Mayo AL staging system or other systems incorporating hs-cTnT. On multivariate analysis, an hs-cTnT alone staging system was independent of period of diagnosis, type of therapy, and NT-proBNP value, the last of which dropped out of the model. Alternate models were explored, but none performed better than the original system or the new hs-cTnT system. Thus, hs-cTnT can be used alone for the staging of disease prognosis. Conclusions A survival model based on hs-cTnT improves the prognostic staging of patients with AL amyloidosis, relegating NT-proBNP to a measure of cardiac response.